There were 1483 (67.8%) patients with tumor size ≤2.5cm, 1853 (70.1%) patients with invasive ductal cancer, 567 (21.8%) patients with positive lymph nodes, 1542 (60.0%) patients with positive ER, 1383 (53.8%) patients with positive PR, and 555 (23.3%) patients with positive HER2. This evidence concerns the gene ERBB2 and neoplasm.